Navigation Links
TNF Blockers May Help Some With Rheumatoid Arthritis

If standard treatment fails, more intensive therapy works well, study finds

THURSDAY, Aug. 6 (HealthDay News) -- Patients with early rheumatoid arthritis (RA) who respond poorly to standard treatment with methotrexate may benefit from additional treatment with tumor necrosis factor (TNF) blockers, a Swedish study suggests.

Previous research has shown that 20 percent to 40 percent of patients have a good response to methotrexate therapy and don't need more intensive combination treatment.

This new study included 487 patients with early RA (less than one year's duration) who were initially treated with methotrexate. After three to four months, the 258 patients with an inadequate response to methotrexate were randomly assigned to receive either the TNF blocker infliximib (Remicade) or the conventional disease-modifying antirheumatic drugs, sulfasalazine and hydroxychloroquine.

After 12 months, 39 percent of patients given infliximib achieved a good response, compared with 25 percent of patients given sulfasalazine and hydroxychloroquine.

"We believe that by treating all patients with methotrexate for 3 to 4 months, we screened out a sizeable proportion [30 percent in this trial] who would have been overtreated if aggressive combination therapy was used for all, an approach that could have increased the risk of side effects and potentially entailed high costs," wrote the researchers from the Karolinska University Hospital and the Karolinska Institute.

A short period of treatment with methotrexate alone, followed by the addition of a TNF blocker only in patients who have an inadequate response to methotrexate, is the best treatment option for patients with early RA, they concluded.

The study appears in this week's edition of The Lancet.

In related news, the U.S. Food and Drug Administration on Tuesday ordered that TNF blockers carry an updated "black box" label to warn doctors and patients that the drugs may increase the risk of cancer in children and adolescents.

More information

The Arthritis Foundation has more about rheumatoid arthritis.

-- Robert Preidt

SOURCE: The Lancet, news release, Aug. 6, 2009

Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Amgen and Wyeth Statement on FDA Announcement About Tumor Necrosis Factor (TNF) Blockers
2. Beta-Blockers Tied to Higher Cataract Risk
3. Questions Continue About Using Beta Blockers Before Surgery
4. Beta Blockers Help Hospitalized Heart Failure Patients
5. Beta Blockers Raise Stroke, Death Risk After Surgery
6. Women are treated less frequently than men with statins, aspirin and beta-blockers
7. Scripps scientists find calcium channel blockers help normalize lysosomal storage disease cells
8. Decision Resources Updated Rheumatoid Arthritis Report Now Includes Forecast for Rigel Pharmaceuticals Fostamatinib Disodium
9. Lexicon Initiates Phase 2 Clinical Trial of LX2931 in Patients With Rheumatoid Arthritis
10. Rigel to Host Conference Call to Discuss Results of Its Phase 2b TASKi3 Clinical Trial of R788 in Rheumatoid Arthritis
11. For Treatment of Rheumatoid Arthritis, Surveyed Rheumatologists and Patients Differ In Their Perception of Bristol-Myers Squibbs Orencia
Post Your Comments:
Related Image:
TNF Blockers May Help Some With Rheumatoid Arthritis
(Date:12/1/2015)... ... December 01, 2015 , ... CloudLIMS today announced that ... Business Awards under the New Products and Services category for its innovative product ... management software that helps labs organize data and track samples with storage ...
(Date:12/1/2015)... New York, NY (PRWEB) , ... December 01, ... ... cause of non-traumatic limb amputations in the United States. Podiatrists are well aware ... (failure to adopt therapeutic behaviors) are often catastrophic contributors to diseases of the ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... ... their independence is everything. That is why Hollister Incorporated has launched the VaPro ... offer this next product in the VaPro touch free catheter portfolio,” said Michael ...
(Date:12/1/2015)... ... December 01, 2015 , ... Next IT Healthcare, ... a finalist in this year’s Fierce Innovation Awards: Healthcare Edition, an awards program ... as a finalist in the category of Digital Solutions for its innovative, industry-leading ...
(Date:12/1/2015)... ... 01, 2015 , ... TCS Healthcare Technologies (TCS), a leading ... arenas, is pleased to announce that VIP Care Services, a Caprock Health Group ... ACUITY Complete Care™ Management to back their collaborative catastrophic case management initiatives. ACUITY ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... , Dec. 1, 2015  Eyeon Therapeutics has ... dry eye treatments based on a charged hydrophilic ... delivery CDMO.  The product has been shown to ... previously published.  Mark Mitchnick , MD, CEO ... protection to additional polymers in conjunction with a ...
(Date:12/1/2015)... , December 1, 2015 --> ... report "Immunotherapy Drugs Market by Type of Drug (Monoclonal Antibodies, ... Epidemiology, Regulatory and Pipeline Analysis - Global Forecast to 2020", ... to reach USD 73,529.2 Million by 2020 from USD 40,281.6 ... to 2020. Browse 37 ...
(Date:12/1/2015)... HERTFORDSHIRE, England , BANGALORE, India ... 2015  Mylan N.V. (NASDAQ, TASE: MYL) today announced ... upon regulatory approval and for developing country markets funded ... + Lamivudine 300 mg + Efavirenz 400 mg) for ... Clinton Health Access Initiative (CHAI) to develop TLE400. The ...
Breaking Medicine Technology: